natgillin/translations-raw huggingface dataset:
The composition for use of any one of claims 1 to 5, wherein the composition is to be administered via an intravenous, intraarterial, intraperitoneal, intravesicular, subcutaneous, intrathecal, intrapulmonary, intramuscular, intratracheal, intraocular, transdermal, oral, or inhalation route. 
Pripravak za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što se pripravak daje putem intravenoznog, intraarterijskog, intraperitonealnog, intravezikularnog, potkožnog, mtratekalnog, intrapulmonalnog, intramuskularnog, intratrahealnog, intraokularnog, transdermalnog, oralnog ili inhalacijskog puta primjene.
Z is CH═CH or S; and each Q is independently phenyl or pyridinyl, each optionally substituted with up to 3 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy; 
Zje CH=CH ili S; i svako Q je nezavisno fenil ili piridinil, svaki izborno supstituiran sa do 3 supstituenta nezavisno izabrana iz grupe koju čine halogen, cijano, Cy-Cu alkil, C,-C, haloalkil, C,-C, alkoksi i C;-Cy haloalkoksi; i
A pharmaceutical composition for use in prophylaxis and/or treatment of prostate carcinoma, the composition comprising a combination of dimethyl isosorbide and a compound selected from compounds having the following formula: wherein a, b and c respectively denote, independently from each other, a single bond or a double bond, with the proviso that at least one of a, b and c represents a double bond, and with the proviso that if a is single bond and b is double bond R2 is not H; 
Farmaceutski oblik za uporabu u prevenciji iili liječenju karcinoma prostate, oblik sadrži kombinaciju dimetil izosorbida 1 spoj izabran između spojeva koji imaju sljedeću formulu: gdje a, bi c odgovarajuće označavaju, nezavisno jedan od drugoga, jednostruku vezu ili dvostruku vezu, uz uvjet da barem jedan od a, b i c predstavlja dvostruku vezu, i uz uvjet da ako je a jednostruka veza i b je dvostruka veza, tada R, nije H;
by the use of a reducing agent like borane, alane or lithium aluminium hydride. 
korištenjem reducirajućg agensa kao što je to boran, alan ili litijev aluminijski hidrid.
determine a switching current ratio of the MTJstructure that reduces a source-loading effect of the memory cell, the switching current ratio representing a ratio of: 
određivanje izmjeničnog omjera MTJ strukture koja smanjuje efekt opterećenja izvora memorijske ćelije, omjer izmjenične struje predstavlja omjer:
Yet another embodiment of the present disclosure may include a method for the control or prevention of fungal attack on a plant, the method including the step of applying a fungicidally effective amount of one or more of the compounds described below to at least one of the fungus, the plant, an area adjacent to the plant, and the seed adapted to produce the plant. 
Postupak za suzbijanje 1 sprječavanje gljivičnog napada na biljku, naznačen time, da postupak uključuje stupnjeve: Nanošenje fungicidno učinkovite količine barem jednog od spojeva iz patentnog zahtjeva 1 na barem jednu biljku, na područje u blizini biljke, na tlo prilagođeno da pospješuje rast biljke, na korijen biljke, krošnju biljke i sjeme prilagođeno za proizvodnju biljke.
CRL-9096] when expressed therein. 
CRL-9096 (CHOdhfr-) kada se tamo eksprimira.
The animals were randomly assigned to 1 of 3 groups. 
Životinje su randomski podijeljene u 1 od 3 skupine.
The crude material is purified by passing through silica gel column (ethyl acetate:methanol, 80:20) which gives 2-(4-aminobut-2-ynyl)-2-methylmalonic acid diethyl ester. Examples 1 and 2 
Sirovi materijal pročisti se propuštanjem kroz stupac silikagela (etil-acetat/metanol, 80:20), čime se dobije dietilni ester 2-(4-aminobut-2-inil)-2-metilmalonske kiseline.
The IL-23 antagonist for use according to Claim 50, wherein the dose of the IL-23 antagonist is gradually reduced during a second treatment period that begins upon the end of the first treatment period. 
. 1L-23 antagonist za uporabu u skladu sa zahtjevom 50, naznačen time, da se doza IL-23 antagonista postupno smanjuje za vrijeme drugog razdoblja liječenja koje započinje završetkom prvog razdoblja liječenja.
is in the form of a pill, tablet, capsule, gelcap, liquid, or emulsion, optionally wherein said pill, tablet, capsule, or gelcap further comprises an enteric coating; and/or 
(ii) u obliku pilule, tablete, kapsule, gel kapsule, tekuća, ili emulzija, opcionalno pri čemu je spomenuta pilula, tableta, ili gel kapsula koja dalje ima enteričan premaz; i/ili
Computer program product configured to provide instructions to carry out a method according to any one of the claims 1 - 8, when loaded on a computer arrangement (156). 
Računalni program podešen da daje upute za provođenje postupka prema bilo kojem od zahtjeva 1 - 8, kada ga se učita u računalo (156).
The back support device and safety bow set according to claim 1, wherein the back support device has a flexibility that springs against and/or absorbs the movements of the user. 
Sredstvo za naslanjanje prema bilo kojem od prethodnih zahtjeva, naznačeno time, da je sredstvo za naglanjanje fleksibilno tako da odbija i/ili apsorbira pokrete korisnika.
One or more oligomers of lactic acid for use in the prophylaxis and/or treatment of gynaecological infections by administering the one or more oligomers of lactic acid to the vagina, wherein the one or more oligomers of lactic acid has the following formula I wherein n is an integer from 2 to 25. 
HR P20140559 T1 PATENTNI ZAHTJEVI Jedan ili više oligomera mliječne kiseline za uporabu u profilaksi iili liječenju ginekoloških infekcija administriranjem jednog ili više oligomera mliječne kiseline u vaginu, pri čemu jedan ili više oligomera mliječne kiseline ima slijedeću formulu I
Apparatus according to one of claims 9 to 12, characterized in that the apparatus further comprises orientating means for orientating the seed before it is opened. 
Uređaj prema jednom od patentnih zahtjeva 8 do 10, naznačen time, da ovaj uređaj nadalje obuhvaća orijentacijsko sredstvo za orijentiranje sjemena prije nego se ono otvori.
The process of clause 69, wherein P1 is a cleavable protecting group. 
Postupak prema patentnom zahtjevu 45, gdje je P" zaštitna grupa koja se može odvojiti.
An ophthalmic device material comprising a benzotriazole compound of claim 1 and a device-forming monomer selected from the group consisting of acrylic monomers and silicone-containing monomers. 
Materijal za očne naprave, naznačen time što sadrži benzotriazolski spoj u skladu s patentnim zahtjevom 1 i monomer za oblikovanje naprave kojeg se bira skupine koju čine akrilni monomeri i monomeri koji sadrže silikon.
The device according to claim 7, wherein a direction of rotation of the helical flow path of the first separating element is opposite a direction of rotation of the helical flow path of the second separating element. A device for generating milk froth, comprising 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što su kod proizvodnje, po želji, vruće ili hladne mliječne pjene prisutna dva paralelna odjeljka puta protoka (7a, 7b), gdje se grijač s kontinuiranim protokom (9) nalazi u prvom od odjeljaka puta protoka (7a).
There are many causes of muscle atrophy, including as a result of treatment with a glucocorticoid such as cortisol, dexamethasone, betamethasone, prednisone, methylprednisolone, or prednisolone. The muscle atrophy can also be a result of denervation due to nerve trauma or a result of degenerative, metabolic, or inflammatory neuropathy (e.g., Guillian-Barré syndrome, peripheral neuropathy, or exposure to environmental toxins or drugs). In addition, the muscle atrophy can be a result of myopathy, such as myotonia; a congenital myopathy, including nemalene myopathy, multi/minicore myopathy and myotubular (centronuclear) myopathy; mitochondrial myopathy; familial periodic paralysis; inflammatory myopathy; metabolic myopathy, such as caused by a glycogen or lipid storage disease; dermatomyositisis; polymyositis; inclusion body myositis; myositis ossificans; rhabdomyolysis and myoglobinurias. 
Protutijelo za uporabu prema zahtjevu 23, naznačeno time, da se kod navedene muskulo-skeletne bolesti ili poremećaja radi o sljedećima: mišićna atrofija, primjerice uzrokovana miopatijom, kao što su miotonija, kongenitalna miopatija, uključujući nemalin-miopatiju, - multi-miopatiju, - minicore-miopatiju i miotubularnu = (centronuklearnu) = miopatiju, mitohondrijsku miopatiju, porodičnu periodičnu paralizu, upalnu miopatiju, metaboličku miopatiju, kao što je ona uzrokovana bolešću sakupljanja lipida ili glikogena, dermatomiositis, polimiositis, miositis ekstremiteta, osifikacijski miositis, rabdomiolizu i mioglobinurije; distrofija kao što su sljedeće: Duchenne, Becker, miotonska, fascioskapulohumeralna, Emery-Dreifuss, okulofaringealna, skapulohumeralna, pojasa udova, Fukuyama, kongenitalna mišićna distrofija, ili urođena distalna miopatija; osteoporoza; lom kosti; kratak stas; patuljatost; produženo trajanje odmora u krevetu; dobrovoljna neaktivnost i/ili nedobrovoljna neaktivnost.
Wakefulness and sleep states were identified as previously described for cats [Petitjean et al., Brain Res., 1975, 88: 439-53] and mice [Valatx and Bugat, Brain Res., 1974, 69: 315-30]. 
Stanja budnosti i spavanja identificirani su, kako je prethodno opisano kod mačaka [Petitjean 1 sur., Brain Res., 1975, 88: 439-531 1 miševa [Valatx i Bugat, Brain Res., 1974, 69; 315-30].
Locking system (1) according to Claim 2, characterized in that the heat transfer element (8) comprises a metal plate. 
Sustav za zabravljivanje (1) u skladu s patentnim zahtjevom 1, naznačen time što element za prijenos topline (8) ima metalnu ploču.
The method of claim 2, wherein R1 represents a hydrocarbon group comprising a straight chain, branched or cyclic group each containing up to 18 carbon atoms. 
R1 predstavlja ugljikovodičnu grupu koja sadrži ravnolančanu, razgranatu ili cikličnu grupu gdje svaka sadrži do 18 atoma ugljika, opcionalno gdje R1 predstavlja metil.
Aqueous slurry according to one of claims 16 to 19, wherein the ball-shaped surface modified calcium carbonate comprising mineral has a narrow particle size distribution d 98/ d 50 preferably smaller than 3, more preferably smaller than 2.5, preferably in a range from 1.4 to 2.9. 
Vodena suspenzija prema jednom od zahtjeva 16 do 19, naznačena time da kugličasti površinski modificirani kalcijev karbonat koji sadrži mineral ima usku distribuciju veličine čestica d98/d50 poželjno manju od 3, poželjnije manju od 2.5, poželjno u rasponu od 1.4 do 2.9.
(Yield 68%) After chromatography on silica gel (50:50:5 benzene-cyclohexane-ethanol) the product had m.p. 
Nakon kromatografije na silika gelu (50:50:5 benzen-cikloheksan-etanol) produkt ima t. t.
In some embodiments, a composition (e.g., a pharmaceutical composition) is provided comprising a compound as described herein and one or more pharmaceutically acceptable excipients. 
7. < Farmaceutska kompozicija koja sadrži spoj iz zahtjeva 6, ili njegovu farmaceutski prihvatljivu sol, i jednu ili više 15 farmaceutski prihvatljivih pomoćnih tvari. 8.
Consequently, separate disintegration means are necessary. 
Prema tome, nužni su odvojeni sklopovi za raspršivanje.
A speargun as claimed in claim 1, wherein the return means consist of at least one pulley (13, 13I, 13II, 13III, 13IV) at the head (10) and/or the body of the speargun. 
Podvodna puška u skladu sa zahtjevom 1, pri čemu sredstvo za vraćanje obuhvaća najmanje jednu remenicu (13, 13I, 13II, 13III, 13IV) na glavi (10) i / ili na trupu podvodne puške.
wherein D is a steroid of the substructure IV: wherein 
Spoj u skladu s patentnim zahtjevom 1, gdje D je steroid podstrukture TV: gdje
The method of embodiment 21, wherein said composition is lyophilized. The method of embodiment 21, wherein said composition is a reconstituted lyophilized composition. The method of embodiment 21, wherein said target cell is selected from the group consisting of hepatocytes, epithelial cells, hematopoietic cells, epithelial cells, endothelial cells, lung cells, bone cells, stem cells, mesenchymal cells, neural cells, cardiac cells, adipocytes, vascular smooth muscle cells, cardiomyocytes, skeletal muscle cells, beta cells, pituitary cells, synovial lining cells, ovarian cells, testicular cells, fibroblasts, B cells, T cells, reticulocytes, leukocytes, granulocytes and tumor cells. 
Sastav za upotrebu prema bilo kojem od patentnih zahtjeva 1-5, koji dalje sadrži agens za olakšavanje prijenosa RNA molekula u intracelularni odjeljak ciljne stanice, opcionalno pri čemu je navedena ciljna stanica izabrana iz grupe koja se sastoji od hepatocita, epitelnih stanica, hematopoetskih stanica, epitelnih stanica, endotelnih stanica, stanica pluća, stanica kostiju, matičnih stanica, mezenhimskih stanica, živčanih stanica, stanica srca, adipocita, stanica vaskularnih glatkih mišića, kardiomiocita, stanica skeletnih mišića, beta stanica, stanica hipofize, stanica sinovijalne ovojnice, stanica jajnika, stanica testisa, fibroblasta, B stanica, T stanica, retikulocita, leukocita, granulocita i tumorskih stanica.
a linear or branched C1-C6 alkyl group, or an aryl group, optionally substituted with an alkoxy group, 
ravnolančasta ili razgranata C1-C6 alkilna skupina ili arilna skupina koja može biti supstituirana alkoksi-skupinom,
optionally mixing the granules of step (3) with the remaining excipients in a mixer to obtain the final mixture; and 
(4) po želji miješanje granula iz koraka (3) s preostalim pomoćnim sredstvima u mješalici da bi se dobila konačna mješavina;
The present invention moreover provides the use of the compounds according to the invention for the preparation of a medicament for treatment and/or prevention of diseases, in particular the abovementioned diseases. 
Uporaba spoja kako je definiran u jednom od zahtjeva 1 do 6 naznačena time da je za pripremu medikamenta za liječenje i/ili sprečavanje kardiovaskularnih bolesti, kardijalne insuficijencije, anemije, kroničnih bolesti bubrega i bubrežne insuficijencije.
Use of a CMAP27 peptide chosen from the group of CMAP27 derivatives according to claim 1, CMAP27 and CMAP26-NH2 as adjuvant. 
Uporaba CMAP27 peptida odabranog iz skupine CMAP27 derivata sukladno zahtjevu 1, naznačena time, da se koristi kao adjuvant.
After sorting as mentioned above, the purified calcium carbonate, e.g. chalk, limestone or marble, is preferably subjected to a dry or wet comminution step. 
Postupak prema zahtjevu 16, naznačen time da se nakon koraka usitnjavanja, čestice kalcijevog karbonata podvrgavaju koraku razvrstavanja.
activating the TPMS sensor; identifying the specific TPMS sensor based on the TPMS sensor identification; 
identificiranja specifičnog TPMS senzora (50) na osnovi identifikacije TPMS senzora;
An important condition for this process to succeed, is that the particle size distributions of the powder components that are fluidized, do not differ too much. 
Važan preduvjet za uspjeh postupka je veličina čestica pojedinih sastojaka praška, koja ne bi smjela biti previše različita.
Propulsion system according to claim 2 wherein said two sections of the arm form fins. 
Pogonski sistem prema jednom od patentnih zahtjeva 1 do 2 gdje navedeni krak (200) nije vodootporan.
Where desired, it is contemplated that sulfate and/or a metal ion other than lead is removed from the regenerated electroprocessing solvent In further contemplated aspects, the cathode is moved relative to the lead ion-enriched electroprocessing solvent during the step of reducing the lead ions, and/or the high-purity lead has a purity of at least 98%, more preferably at least 99%, and most preferably at least 99.5%. 
Postupak sukladno patentnom zahtjevu 7 pri čemu olovo visoke čistoće ima čistoću od najmanje 98%, ili pri čemu se prijanjajuće olovo visoke čistoće uklanja površinskim prikupljačem na način koji nije ljuštenje; i pri čemu je površina prikupljača postavljena u blizini katode, ili pri čemu je prijanjajuće olovo visoke čistoće koje prijanja mikro ili nanoporozno miješana matrica gustoće manje od 5 g/em'.
Process according to any of the preceding claims, wherein, before said step c), the mold is covered at least partially by a material in order to confer special aesthetic effects on the surface of the final product. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da, se prije spomenutog koraka c), kalup barem djelomično prekriva s materijalom, kako bi se na površini konačnog proizvoda izveli posebni estetski efekti.
The back edge is preferably displaced inwards towards to internal area of each two sides of the inner part so that the back part be on level with the outermost edge of the back side of the packaging when the packaging is closed. 
Poželjno je da se stražnji rub pomakne prema unutra i to prema unutarnjem prostoru svake od dviju strana unutarnjeg dijela, tako da je stražnji dio na nivou s krajnjim rubom stražnje strane pakiranja kada je pakiranje zatvoreno.
The TGFß antagonist for use according to any one of claims 1 or 4-11, wherein said TGFß antagonist is co-administered with capecitabine and ixabepilone. 
Antagonist TGFB za uporabu u skladu sa zahtjevom 1, naznačen time što se navedeni antagonist TGFB primjenjuje zajedno s kapecitabinom i iksabepilonom.
The bandage of claim 2, comprising a second layer of cotton gauze. 
Zavoj u skladu sa zahtjevom 19, naznačen time, što obuhvaća sekudarni sloj pamučne gaze.
The composition of claim 1, wherein the variable regions of the 1st and the 2nd antibody heavy chains of the one antibody in the mixture recognize different target epitopes, whereas the variable regions of the 1st and the 2nd antibody heavy chains of the second antibody in the mixture recognize the same target epitope. 
Postupak u skladu patentnim zahtjevom 7, naznačen time što varijabilne regije prvog i drugog polipeptidnog lanca koji sadrže CH3 domenu prepoznaju različite ciljne epitope, pri čemu varijabilne regije trećeg i četvrtog polipeptidnog lanca koji sadrže CH3 domenu prepoznaju iste ciljne epitope.
effecting a nitration of the compound prepared in step (a) with a nitrating agent in the presence of a carboxylic anhydride, preferably acetic anhydride. 
(b) nitriranje spoja proizvedenog u stupnju (a) sa sredstvom za nitriranje u prisutnosti karboksilnog anhidrida, ponajprije octenog anhidrida.
The information system according to claim 11, wherein the electronic circuit board is screwed with a screw to the spacer. 
Informacijski sustav u skladu sa patentnim zahtjevom 10, gdje je elektronska ploča (1) strujnog kruga pričvršćena vijkom za razdjelnik.
iii) benzofused heterocyclyl attached via a carbon atom, and when the heterocyclyl portion contains a nitrogen atom, the nitrogen atom is optionally substituted with one substituent selected from the group consisting of C3-7cycloalkylcarbonyl; C3-7cycloalkylsulfonyl; phenyl; phenylcarbonyl; thienylcarbonyl; pyrrolylcarbonyl; phenylsulfonyl; phenyl(C1-4)alkyl; (C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; C1-6alkylcarbonyl-C1-4alkyl; C1-6alkylsulfonyl; pyrimidinyl; and pyridinyl; wherein C3-7cycloalkylcarbonyl, phenyl, phenylcarbonyl, phenyl(C1-4)alkyl and phenylsulfonyl are optionally substituted with trifluoromethyl or one to two fluoro substituents; and wherein benzofused heterocyclyl is optionally substituted at a carbon atom with oxo and optionally independently substituted with one to two additional substituents selected from the group consisting of phenyl, bromo, and C1-4alkyl; iv) phenoxathiinyl; 
pri čemu su navedeni heteroaril i 5,6-dihidro-4H-ciklopentapirazol-2-il opciono supstituirani sa jednim fenil supstituentom, i navedeni fenil je opciono supstituiran sa jednim do dva kloro supstituenta ili trifluorometilom; i pri čemu su fenil od C6-10arila i heteroaril opciono nezavisno supstituirani sa jednim do dva supstituenta izabrana iz grupe koju čine C1-4alkil; cijanometil; C1-4alkoksi; jedan do tri fluoro ili kloro supstituenta; trifluorometil; trifluorometoksi; C1-4alkilkarbonil; C14alkoksikarbonil(C2-4)alkenil; cijano(C2-4)alkenil; (2-cijano)etilaminokarbonil; cijano; aminokarbonil; formil; nitro; bromo; hidroksi; di(C14alkil)aminosulfonil; C1-4alkilsulfonil; -OCH2O- vezan na susjednim atomima ugljika; i NRcRd;pri čemu Rc je vodik ili C1-6alkil i pri čemu Rd je vodik, C1-6alkil, C1-6alkilkarbonil, C1-6alkoksikarbonil, i C14alkilsulfonil;
Nucleic acid according to item 1 to 3, wherein the nucleic acid is an RNA, preferably an mRNA. 
Nukleinska kiselina za uporabu prema zahtjevu 1 do 4, naznačena time da je nukleinska kiselina RNK, poželjno mRNK.
The combined chloroform layers were dried over anhydrous magnesium sulphate and after filtration the solvent was removed at reduced pressure to give a brown oil (14.35 g, yield > 100% - probable solvent remains in product). 
Spojeni slojevi kloroforma se suše iznad anhidridnog magnezij sulfata i nakon filtriranja otapalo se ukloni uz smanjeni tlak dajući smeđe ulje (14.35 g, prinos > 100% - vjerojatno od zaostalog otapala u produktu).
A pharmaceutical composition comprising the liposome of any preceding claim. The liposome of claims 1-11, or the pharmaceutical composition of claim 12, for use in a method for raising a protective immune response in a vertebrate, comprising the step of administering to the vertebrate an effective amount of said liposome, or said pharmaceutical composition. 
Liposom u skladu s patentnim zahtjevima 1-11, ili farmaceutski pripravak u skladu s patentnim zahtjevom 12, namijenjeni upotrebi u postupku postizanja zaštitnog imunosnog odgovora kod kralježnjaka, naznačeni time što se upotreba obuhvaća primjenu na kralježnjaku djelotvorne količine navedenog liposoma, ili navedenog farmaceutskog pripravka.
Further said dry ball-shaped surface modified calcium carbonate containing mineral, has a median grain diameter of from 4 um to about 100 um, preferably from about 5 um to about 75 um, more preferably from about 10 pm to about 50 um, still more preferably from about 15 um to about 30 um. FIG. 
Površinski modificirani kalcijev karbonat koji sadrži mineral prema zahtjevu 21, naznačen time da površinski modificirani kalcijev karbonat koji sadrži mineral ima medijan promjera zrna od 4 um do oko 100 um, poželjno od oko 5 um do oko 75 um, poželjnije od oko 10 um do oko 50 um, još poželjnije od oko 15 um do oko 30 um, određeno s uređajem Malvern Mastersizer.
wherein the liquid treatment composition and the ink are deposited simultaneously or consecutively and the first pattern and the second pattern overlap at least partially. The method of claim 1, wherein the first pattern and the second pattern overlap by at least 50%. 
Postupak prema zahtjevu 1, naznačen time da se prvi uzorak i drugi uzorak preklapaju za barem 50 %, poželjno barem 75 %, poželjnije barem 90 %, još poželjnije barem 95 %, i najpoželjnije barem 99 %.
the HER3 ligand-dependent phosphorylation assay uses stimulated MCF7 cells in the presence of neuregulin (NRG). 
fosforilacijska analiza ovisna o HER3-ligandu, upotrebljava stimulirane MCF7-stanice u prisutnosti neuregulina (NRG).